Immuno-Oncology 360°

Memo

The 8th Annual Immuno-Oncology 360° Delivers Three Key Benefits:- Access to KOLs driving the science- Partnership opportunities with all stakeholders in Immuno-Oncology- Presentations on the latest data impacting the science, clinical and business advancements in Immuno-Oncology2022 Key Topic Areas- Discovery/Preclinical Science- Cell and Gene Therapy- Translational Science- Bispecifics- Clinical Developments- Neoadjuvant/Adjuvant Data- Emerging Biomarkers- Cytokines- Clinical Operations- IO Combinations- Imaging Advancements- Business DevelopmentsImmuno-Oncology 360° reports on the most current data and rapid advancements to help IO stakeholders:- Be at the forefront of the most relevant research and developments from key leadership who are at the pulse of cancer immunotherapy- Foster collaboration amongst those working in all aspects of cancer immunotherapy together under one roof- Partner to expand technology platforms to develop therapeutics at an accelerated rate- Receive the latest pre-clinical, translational and clinical data from academia and industry- Create and prioritize strategies targeted toward specific tumor types- Identify and gain a greater understanding of what assets are available for potential combinations- Hear from IO clinical trial leaders as they cover trial design, clinical operations, the latest outcomes and lessons learned- Get key investor and analyst evaluations and insights on the IO landscape, challenges and what's next- Learn about biomarker advancements in vaccines, imaging, neoantigen approaches and more- Obtain coverage on a wide range of emerging technologiesURLs:Tickets: https://go.evvnt.com/976663-2?pid=5569Sponsor: https://go.evvnt.com/976663-3?pid=5569Brochure: https://go.evvnt.com/976663-4?pid=5569Prices:Standard Industry: USD 2095.0,Academia, Non-Profit and Government=: USD 1047.5Speakers: Adrelia Allen, PharmD, Merck Research Labs, Sarah Anderson, Worldwide Clinical Trials, Andrew Baum, MD, Citi, Roy Baynes, MD, PhD, Merck Research Laboratories, Jake Becraft, PhD, Strand Therapeutics, Sharon Benzeno, PhD, Adaptive Biotechnologies, Jeffrey Bockman, PhD, Cello Health BioConsulting, Oliver Bohnsack MD, PhD, MBA, Calyx, Mark Bonyhadi, PhD, Qiming Venture Partners, Christine Brown, PhD, City of Hope, Lisa Butterfield, PhD, Parker Institute for Cancer Immunotherapy, Matt Call, MBA, iTeos Therapeutics, Tina Cascone, MD, PhD, MD Anderson Cancer Center, Jonathan Cheng, MD, BMS, Daniel Chen, MD, PhD, Society for Immunotherapy of Cancer (SITC), Elaine Cheung, Lyell Immunopharma, Alex de Crespigny, PhD, Genentech, Jakob Dupont, MD, Atara Biotherapeutics, Ariella Evenzahav, PhD, BeiGene, Jonathan Fassberg, Oppenheimer, Antonio "Tito" Fojo, MD, PhD, Columbia University, Joseph Fraietta, PhD, University of Pennsylvania, Thomas Gajewski, MD, PhD, University of Chicago, Charles Glaus, PhD, Bayer US-Pharmaceuticals, Michael Groaning, PhD, Amgen, James Gulley, MD, PhD, National Cancer Institute, NIH, Ira Gupta, MD, GSK, Nick Haining, MD, Arsenal Bio, Rachel Haurwitz, PhD, Caribou Biosciences, Priti Hegde, PhD, Foundation Medicine, Kristen Hege, MD, BMS, Axel Hoos, MD, PhD, Scorpion Therapeutics, Nouhad Husseini, MBA, Regeneron, Ramy Ibrahim, MD, Bit Bio, Margit (Maggie) Janat-Amsbury, MD, PhD, Amgen, Michael Kalos, PhD, Next Pillar Consulting, Vassiliki (Valia) Karantza, MD, PhD, Merck, Ron Korn, MD, PhD, Imaging Endpoints, Joanne Lager, MD, iTeos Therapeutics, Mark Kotter, MD, PhD, bit.bio, Jeff Legos, PhD, MBA, Novartis, David Leung, MD, PhD, BMS, Zihai Li, MD, PhD, Ohio State University, John Lo, BMS, Irina Margine, PhD, Wellington Management, Sanjeev Mariathasan, PhD, Genentech, Peter Marks, MD, PhD, Center for Biologics Evaluation and Research (CBER), FDA, Julie Martin, MBA, Scimega, Cristian Massacesi, MD, AstraZeneca, Lei Meng, MBA, Avidity Partners, Patrick Murphy, PhD, 10x Genomics, Lynn Navale, Allogene Therapeutics, Erin Newburn, PhD, Personalis, Inc, Shree Patel, PhD, Achilles Therapeutics, Andrea Perrone, MD, Merck, Karen Peterson, Cancer Survivor and Patient Advocate, Lilli Petruzzelli, Genentech,  Michael Polansky, Parker Group, Prakash Raman, PhD, Flagship Pioneering, Chetna Rao, PhD, BMS, Celeste Richardson, PhD, Catamaran Bio, Angel A Rodriguez, MD, Natera, Rob Ross, MD, Surface Oncology, Marco Ruella, MD, University of Pennsylvania, Peter Sandor, MD, MBA, Astellas Pharma US, Barbra Sasu, PhD, Allogene Therapeutics, Aiman Shalabi, PharmD, GSK, Matthew Silva, PhD, Invicro, John Simmons, PhD, Natera, Mark Simon, MBA, Torreya Partners, Otello Stampacchia, PhD, Omega Funds, Zhen Su, MD, MBA, Marengo Therapeutics, Ryan Sullivan, MD, Harvard Medical School,  Zach Taylor, MBA, BioNTech US, Suzanne Topalian, MD, Johns Hopkins University, Samik Upadhaya, PhD, Cancer Research Institute (CRI), Bahram (Bob) Valamehr, PhD, Fate Therapeutics, Raluca Verona, PhD, Janssen R and D, Robert Vonderheide, MD, DPhil, University of Pennsylvania, Jeremy Waight, PhD, GSK, Bei Wang, MD, PhD, Regeneron, Christine Ward, PhD, Takeda, Jon Waterman-Smith, Nilogen Oncosystems, Danny Wells, PhD, ImmunAI, Holger Wesche, PhD, Harpoon Therapeutics, Keith Wharton, MD, PhD, Ultivue, John Wherry, PhD, University of Pennsylvania School of Medicine, Jon Wigginton, MD, Cullinan Oncology, Simon Williams, PhD, Genentech, Francesca Zolezzi, PhD, Syneos HealthDate and Time: On Wednesday March 16, 2022 at 7:30 am (ends Friday March 18, 2022 at 4:00 pm)Venue Details: New York Marriott at the Brooklyn Bridge, 333 Adams Street, Brooklyn, New York, 11201, United States